Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) have been assigned an average rating of “Moderate Buy” from the eleven research firms that are presently covering the company, MarketBeat reports. Two research analysts have rated the stock with a sell rating, seven have given a buy rating and two have given a strong buy rating to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $16.60.

A number of analysts recently commented on the company. Wedbush reaffirmed an “outperform” rating and set a $23.00 price target on shares of Y-mAbs Therapeutics in a research report on Monday, March 3rd. Oppenheimer reduced their price objective on Y-mAbs Therapeutics from $21.00 to $20.00 and set an “outperform” rating for the company in a research note on Wednesday, May 14th. Morgan Stanley lowered their target price on Y-mAbs Therapeutics from $11.00 to $7.00 and set an “underweight” rating on the stock in a research note on Wednesday, March 5th. HC Wainwright reduced their price target on shares of Y-mAbs Therapeutics from $12.00 to $11.00 and set a “buy” rating for the company in a research report on Monday. Finally, Bank of America downgraded shares of Y-mAbs Therapeutics from a “neutral” rating to an “underperform” rating and set a $3.00 price objective for the company. in a report on Tuesday, April 22nd.

Insider Buying and Selling at Y-mAbs Therapeutics

In related news, insider Thomas Gad sold 10,810 shares of the company’s stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $5.23, for a total transaction of $56,536.30. Following the sale, the insider now directly owns 202,721 shares in the company, valued at approximately $1,060,230.83. This represents a 5.06% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 22.50% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Barclays PLC boosted its holdings in shares of Y-mAbs Therapeutics by 433.4% in the third quarter. Barclays PLC now owns 69,222 shares of the company’s stock worth $910,000 after acquiring an additional 56,244 shares during the period. JPMorgan Chase & Co. boosted its stake in Y-mAbs Therapeutics by 10.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 30,335 shares of the company’s stock worth $399,000 after purchasing an additional 2,854 shares during the period. SG Americas Securities LLC grew its holdings in Y-mAbs Therapeutics by 30.7% during the 4th quarter. SG Americas Securities LLC now owns 17,729 shares of the company’s stock valued at $139,000 after buying an additional 4,163 shares in the last quarter. Principal Financial Group Inc. increased its position in shares of Y-mAbs Therapeutics by 9.4% during the fourth quarter. Principal Financial Group Inc. now owns 22,197 shares of the company’s stock valued at $174,000 after buying an additional 1,903 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of Y-mAbs Therapeutics by 1.8% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 284,540 shares of the company’s stock worth $2,228,000 after buying an additional 4,963 shares in the last quarter. 70.85% of the stock is currently owned by hedge funds and other institutional investors.

Y-mAbs Therapeutics Price Performance

NASDAQ YMAB opened at $4.17 on Thursday. The company has a fifty day moving average price of $4.45 and a 200-day moving average price of $6.93. The firm has a market cap of $188.83 million, a price-to-earnings ratio of -7.72 and a beta of 0.53. Y-mAbs Therapeutics has a 1 year low of $3.55 and a 1 year high of $16.11.

Y-mAbs Therapeutics (NASDAQ:YMAB) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.10. The business had revenue of $20.90 million during the quarter, compared to the consensus estimate of $19.97 million. Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. On average, research analysts anticipate that Y-mAbs Therapeutics will post -0.65 EPS for the current fiscal year.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.